BioCryst Pharmaceuticals GAAP EPS de US$ 0,14 supera US$ 0,06, receita de US$ 180,29 milhões supera US$ 14,61 milhões

BioCryst Q3 earnings beat estimates on EPS and revenue, with higher 2026 total revenue guidance.